Multidrug-resistant Acinetobacter baumannii (MDR-AB) presents a critical challenge to human health. In 2017, the World Health Organization identified carbapenem-resistant A. baumannii as a 'Critical' pathogen that urgently requires novel treatment options [1]. Despite their nephrotoxicity, polymyxins are stated as a last-line therapeutic against MDR-AB outbreaks. Due to the rapid emergence of resistance during antibiotic monotherapy, synergistic combinations of polymyxin with some other antibiotics are recommended for the treatment of MDR-AB infections [2]. One of antibiotic complexes that can resist MDR-AB is the combination of polymyxins with trimethoprim-sulfamethoxazole. However, this combination of antibiotics, like most other combination therapies, is mostly empirical, so research is needed to understand the mechanism of synergistic antibacterial action. The objective of this study was to determine the distribution of multidrug resistance phenotypes of A. baumannii in 61 clinical isolates collected in 2013-2019 from hospital of Lithuanian National Cancer Institute.
Isolates were identified as A. baumannii by conventional microbiological methods and confirmed by species-specific PCR for the blaOXA-51-like and rRNR genes. Following that, minimum inhibitory concentrations (MICs) for meropenem (carbapenem), gentamicin (aminoglycoside), ciprofloxacin (fluoroquinolone) and trimethoprim-sulfamethoxazole were determined according to EUCAST guidelines [3].
Our preliminary results showed that 83% of A. baumannii clinical isolates are resistant to meropenem (MIC > 8mg/L), 88% - to gentamicin (MIC > 4mg/L), 88% - to ciprofloxacin (MIC > 1mg/L). Interestingly, we stated that only 39% of A. baumannii isolates are resistant to trimethoprim-sulfamethoxazole treatment (MIC> 4mg/L). Our preliminary results indicate that 8,7% of isolates are extensively-drug resistant (XDR) and 78,3% are multidrug-resistant (MDR).
Resistance to sulfamethoxazole was studied further by PCR of dihydropteroate synthetase inhibitor genes (sul1, sul2, sul3). Out of isolates possessing sul1 gene, 87% were resistant to trimethoprim-sulfamethoxazole. 100% of isolates found to have sul2 were resistant, and sul3 was not found in the collection.
Cell permeability barrier is considered an important mechanism of resistance for antibiotic treatment. Therefore we attempted to detect ade genes as a sign of active efflux systems. The presence of adeA, adeB, adeJ was investigated by PCR. adeA was found in 90% of isolates, adeB in 84% of isolates, adeJ in 98% of all isolates, however no clear correlation was observed with resistance to individual antibiotics.
In Lithuania, 78,5% of studied A. baumannii isolates have been shown to be multidrug-resistant [4]. Our results confirmed that A. baumannii antibiotic resistance is a serious problem in Lithuanian National Cancer Institute hospital (MDR phenotype - 78,3%). Therefore hospitals should strengthen the surveillance of this opportunistic pathogen in hospital environments. Additionally, further examination of mechanisms for effective MDR-AB killing are needed to prevent infections.